vs
Side-by-side financial comparison of Peraso Inc. (PRSO) and Sensus Healthcare, Inc. (SRTS). Click either name above to swap in a different company.
Sensus Healthcare, Inc. is the larger business by last-quarter revenue ($4.9M vs $2.9M, roughly 1.7× Peraso Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -64.1%, a 20.8% gap on every dollar of revenue. On growth, Peraso Inc. posted the faster year-over-year revenue change (-22.0% vs -62.2%). Over the past eight quarters, Peraso Inc.'s revenue compounded faster (1.0% CAGR vs -31.9%).
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
Sensus Healthcare, Inc. is a medical technology company that designs, manufactures and commercializes innovative non-invasive superficial radiation therapy systems. Its products are primarily used for treating non-melanoma skin cancers, keloids, and select cosmetic dermatology conditions, serving healthcare providers and clinical facilities worldwide.
PRSO vs SRTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9M | $4.9M |
| Net Profit | $-1.2M | $-3.2M |
| Gross Margin | 52.2% | 38.4% |
| Operating Margin | -44.6% | -63.8% |
| Net Margin | -43.3% | -64.1% |
| Revenue YoY | -22.0% | -62.2% |
| Net Profit YoY | 20.3% | -304.9% |
| EPS (diluted) | $-0.09 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9M | $4.9M | ||
| Q3 25 | $3.2M | $6.9M | ||
| Q2 25 | $2.2M | $7.3M | ||
| Q1 25 | $3.9M | $8.3M | ||
| Q4 24 | $3.7M | $13.1M | ||
| Q3 24 | $3.8M | $8.8M | ||
| Q2 24 | $4.2M | $9.2M | ||
| Q1 24 | $2.8M | $10.7M |
| Q4 25 | $-1.2M | $-3.2M | ||
| Q3 25 | $-1.2M | $-943.0K | ||
| Q2 25 | $-1.8M | $-1.0M | ||
| Q1 25 | $-471.0K | $-2.6M | ||
| Q4 24 | $-1.6M | $1.5M | ||
| Q3 24 | $-2.7M | $1.2M | ||
| Q2 24 | $-4.4M | $1.6M | ||
| Q1 24 | $-2.0M | $2.3M |
| Q4 25 | 52.2% | 38.4% | ||
| Q3 25 | 56.2% | 39.4% | ||
| Q2 25 | 48.3% | 39.7% | ||
| Q1 25 | 69.3% | 52.2% | ||
| Q4 24 | 56.3% | 54.4% | ||
| Q3 24 | 47.0% | 59.3% | ||
| Q2 24 | 55.5% | 58.7% | ||
| Q1 24 | 46.4% | 62.5% |
| Q4 25 | -44.6% | -63.8% | ||
| Q3 25 | -36.8% | -37.3% | ||
| Q2 25 | -80.0% | -26.6% | ||
| Q1 25 | -13.3% | -31.7% | ||
| Q4 24 | -44.3% | 13.2% | ||
| Q3 24 | -70.3% | 16.9% | ||
| Q2 24 | -105.6% | 21.5% | ||
| Q1 24 | -128.9% | 27.1% |
| Q4 25 | -43.3% | -64.1% | ||
| Q3 25 | -37.4% | -13.7% | ||
| Q2 25 | -82.4% | -14.2% | ||
| Q1 25 | -12.2% | -30.8% | ||
| Q4 24 | -42.4% | 11.8% | ||
| Q3 24 | -70.6% | 13.7% | ||
| Q2 24 | -104.4% | 17.4% | ||
| Q1 24 | -72.1% | 21.3% |
| Q4 25 | $-0.09 | $-0.19 | ||
| Q3 25 | $-0.17 | $-0.06 | ||
| Q2 25 | $-0.31 | $-0.06 | ||
| Q1 25 | $-0.10 | $-0.16 | ||
| Q4 24 | $0.36 | $0.10 | ||
| Q3 24 | $-0.98 | $0.07 | ||
| Q2 24 | $-1.88 | $0.10 | ||
| Q1 24 | $-1.07 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.9M | $22.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.6M | $48.1M |
| Total Assets | $6.1M | $53.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $22.1M | ||
| Q3 25 | — | $24.5M | ||
| Q2 25 | — | $22.2M | ||
| Q1 25 | — | $19.1M | ||
| Q4 24 | $3.3M | $22.1M | ||
| Q3 24 | $1.3M | $22.6M | ||
| Q2 24 | $1.9M | $19.0M | ||
| Q1 24 | $2.4M | $14.7M |
| Q4 25 | $4.6M | $48.1M | ||
| Q3 25 | $3.6M | $51.2M | ||
| Q2 25 | $3.0M | $52.1M | ||
| Q1 25 | $3.6M | $53.0M | ||
| Q4 24 | $3.5M | $55.8M | ||
| Q3 24 | $2.0M | $54.1M | ||
| Q2 24 | $3.6M | $52.9M | ||
| Q1 24 | $6.7M | $51.2M |
| Q4 25 | $6.1M | $53.0M | ||
| Q3 25 | $6.2M | $58.3M | ||
| Q2 25 | $5.5M | $58.9M | ||
| Q1 25 | $6.7M | $60.2M | ||
| Q4 24 | $7.2M | $62.2M | ||
| Q3 24 | $7.2M | $59.9M | ||
| Q2 24 | $9.8M | $58.2M | ||
| Q1 24 | $11.5M | $57.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-2.2M |
| Free Cash FlowOCF − Capex | — | $-2.4M |
| FCF MarginFCF / Revenue | — | -47.9% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $332.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-2.2M | ||
| Q3 25 | $-1.5M | $2.3M | ||
| Q2 25 | $-2.0M | $3.1M | ||
| Q1 25 | $-966.0K | $-2.7M | ||
| Q4 24 | $-687.0K | $-827.0K | ||
| Q3 24 | $-683.0K | $4.0M | ||
| Q2 24 | $-659.0K | $4.2M | ||
| Q1 24 | $-2.5M | $-8.2M |
| Q4 25 | — | $-2.4M | ||
| Q3 25 | $-1.6M | $2.3M | ||
| Q2 25 | — | $3.1M | ||
| Q1 25 | — | $-2.7M | ||
| Q4 24 | — | $-1.1M | ||
| Q3 24 | — | $3.6M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $-8.4M |
| Q4 25 | — | -47.9% | ||
| Q3 25 | -48.9% | 33.3% | ||
| Q2 25 | — | 42.2% | ||
| Q1 25 | — | -32.2% | ||
| Q4 24 | — | -8.6% | ||
| Q3 24 | — | 40.9% | ||
| Q2 24 | — | 45.8% | ||
| Q1 24 | — | -79.0% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 1.1% | 0.1% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 2.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.53× | ||
| Q3 24 | — | 3.25× | ||
| Q2 24 | — | 2.62× | ||
| Q1 24 | — | -3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
SRTS
| Products | $2.8M | 57% |
| Other | $2.1M | 43% |
